Special Issue "Thyroid Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (22 December 2019).
Interests: genomic instability; tumor molecular genetics and cytogenetics; thyroid tumor biology; stem-like cancer cells; telomere
Interests: pathology; surgical pathology; oncologic pathology; endocrine pathology; thyroid pathology; molecular pathology; molecular oncology
The incidence of thyroid cancer has dramatically increased in the last 40 years, due to both an improved detection of small (<2 cm) thyroid nodules by neck ultrasonography and a true escalation in thyroid cancer incidence. In spite of this dramatic increase, the vast majority (more than 85%) of thyroid cancer patients are cured by initial treatment and mortality is stably low. This claims for the need of precise parameters able to distinguish between indolent and clinically aggressive nodules, to avoid overtreatment and to accurately identify those tumors that require a more aggressive therapy. Molecular biology has been of great benefit in this respect, and new classifications, taking into account molecular parameters, have recently been introduced, defining new subclasses of thyroid tumors. The aim of this Special Issue is to provide an overview of recent developments in understanding the biology and molecular oncology of thyroid tumors of follicular cell derivation and their repercussions on the diagnosis, prognosis and therapy.
We particularly welcome contributions on all aspects related to thyroid tumors of follicular origin, in the form of either original research articles, concise reviews, or shorter perspective articles. Articles with mechanistic and functional insights from a cellular and molecular biological perspective are especially welcome.
Relevant topics include, but are not limited to:
- Molecular pathology of follicular cell derived thyroid cancer
- Preoperative evaluation of thyroid nodules: ultrasonography
- Preoperative evaluation of thyroid nodules: cytopathology
- Thyroid tumors in children
- Radiation-induced thyroid cancer
- The role of Chemokines in Thyroid Cancer Microenvironment
- The role of miRNA and long non coding RNA in thyroid cancer
- The role of precision thyroid cancer medicine
- Thyroid cancer stem and progenitor cells
- Radioiodine-refractory thyroid cancer
- Tyrosine kinase inhibitors
- Immunotherapy for thyroid carcinoma
- Thyroid cancer proteomics
- Thyroid cancer metabolomics
Prof. Roberta Vanni
Prof. Giovanni Tallini
Prof. Efisio Puxeddu
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- thyroid cancer
- follicular cells
- cancer molecular profiling
- cancer development
- cancer progression
- advanced thyroid cancer
- cancer therapy
- tyrosine kinase inhibitors